Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma

Journal of Clinical Oncology

Volumn 30, Issue 33, 2012, Pages 4077-4083

  Schmidt, Jan ^a   Abel, Ulrich ^a   Debus, Jürgen ^a   Harig, Sabine ^a   Hoffmann, Katrin ^a   Herrmann, Thomas ^a   Bartsch, Detlef ^b   Klein, Justus ^c   Mansmann, Ulrich ^d   Jäger, Dirk ^a   Capussotti, Lorenzo ^f   Kunz, Reiner ^e   Büchler, Markus W ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Hospital of Beilefeld   (Germany)

^c Hospital Herford   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e St Joseph Hospital Berlin   (Germany)

^f MAURIZIANO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; FLUOROURACIL; FOLINIC ACID; RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PANCREAS ADENOCARCINOMA; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; CISPLATIN; FEMALE; FLUOROURACIL; HUMANS; INTERFERON-ALPHA; LEUCOVORIN; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS;

EID: 84869464216     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.2960     Document Type: Article

References (27)

1. Raraty MG, Magee CJ, Ghaneh P, et al: New techniques and agents in the adjuvant therapy of pancreatic cancer. Acta Oncol 41:582-595, 2002
2. Neoptolemos J, Stocken D, Friess H, et al: The final results of the European Study Group for Pancreatic Cancer randomized controlled trial of adjuvant chemoradiotherapy and chemotherapy in patients with resectable pancreatic cancer. N Engl J Med 350:1200-1210, 2004
3. Oettle H, Post S, Neuhaus P, et al: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 297:267-277, 2007
4. Neoptolemos JP, Stocken DD, Bassi C, et al: Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: A randomized controlled trial. JAMA 304:1073-1081, 2010
5. Picozzi VJ, Kozarek RA, Traverso LW: Interferonbased adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 185:476-480, 2003
6. Picozzi J, Abrams R, Traverso L, et al: ACOSOG Z05031: Report on a multicenter, phase II trial for adjuvant therapy of resected pancreatic cancer using cisplatin, 5- FU, and alpha-interferon. J Clin Oncol 26:214s, 2008 (suppl; abstr 4505)
7. Ma JH, Patrut E, Schmidt J, et al: Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma. World J Gastroenterol 11:1521-1528, 2005
8. Schmidt J, Patrut EM, Ma J, et al: Immunomodulatory impact of interferon-alpha in combination with chemoradiation of pancreatic adenocarcinoma (CapRI). Cancer Immunol Immunother 55:1396-1405, 2006
9. Hoffmann K, Mehrle S, Schmidt J, et al: Interferon-alpha restitutes the chemosensitivity in pancreatic cancer. Anticancer Res 28:1499-1507, 2008
10. Zhu Y, Tibensky I, Schmidt J, et al: Interferon-alpha in combination with chemotherapy has potent antiangiogenic properties in an orthotopic mouse model for pancreatic adenocarcinoma. J Immunother 31:28-33, 2008
11. Zhu Y, Tibensky I, Schmidt J, et al: Interferon-alpha enhances antitumor effect of chemotherapy in an orthotopic mouse model for pancreatic adenocarcinoma. J Immunother 31:599-606, 2008
12. Iacopino F, Ferrandina G, Scambia G, et al: Interferons inhibit EGF-stimulated cell growth and reduce EGF binding in human breast cancer cells. Anticancer Res 16:1919-1924, 1996
13. Pfeffer LM, Dinarello CA, Herberman RB, et al: Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 58:2489-2499, 1998
14. Holsti LR, Mattson K, Niiranen A, et al: Enhancement of radiation effects by alpha interferon in the treatment of small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 13:1161-1166, 1987
15. Kurzrock R, Talpaz M, Guttermann J: Interferons: Clinical Applications. Philadelphia, PA, Lippincott, 1991
16. Decatris M, Santhanam S, O'Byrne K: Potential of interferon-alpha in solid tumours: Part 1. BioDrugs 16:261-281, 2002
17. Solorzano CC, Hwang R, Baker CH, et al: Administration of optimal biological dose and schedule of interferon alpha combined with gemcitabine induces apoptosis in tumor-associated endothelial cells and reduces growth of human pancreatic carcinoma implanted orthotopically in nude mice. Clin Cancer Res 9:1858-1867, 2003
18. Marrack P, Kappler J, Mitchell T: Type I interferons keep activated T cells alive. J Exp Med 189:521-530, 1999
19. Matikainen S, Sareneva T, Ronni T, et al: Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells. Blood 93:1980-1991, 1999
20. Paquette RL, Hsu NC, Kiertscher SM, et al: Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J Leukoc Biol 64:358-367, 1998
21. Knaebel HP, Märten A, Schmidt J, et al: Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma - CapRI: Study protocol [ISRCTN62866759]. BMC Cancer 5:37, 2005
22. Hoffmann K, Märten A, Lindel K, et al: Major combined electrolyte deficiency during therapy with low-dose cisplatin, 5-fluorouracil and interferon alpha: Report on several cases and review of the literature [ISRCTN62866759]. BMC Cancer 6:128, 2006
23. Fitzsimmons D, Johnson CD, George S, et al: Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer: EORTC Study Group on Quality of Life. Eur J Cancer 35:939-941, 1999
24. Radloff L: The CES-D scale: A new self report depression scale for research in the general population. Appl Psych Meas 1:385-401, 1977
25. Collett D: Modelling Survival Data in Medical Research. London, United Kingdom, Chapman & Hall, 1994
26. Machin D, Weeden S: Suggestions for the presentation of quality of life data from clinical trials. Stat Med 17:711-724, 1998
27. Sorg C, Schmidt J, Büchler M, et al: Examination of external validity in randomized controlled trials for adjuvant treatment of pancreatic adenocarcinoma. Pancreas 38:542-550, 2009